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Abstract: Urologic tumors continue to represent a huge fraction of cancer cases in the
United States, with over 376,310 estimated new diagnoses in 2013. As with many types of
tumors, urologic tumors vary greatly in their phenotype, ranging from minimally invasive
to malignancies possessing great metastatic potential. The increasing need for more
efficient and less invasive methods of cancer detection, as well as the ability to predict
severity of the disease phenotype is readily evident—yet reliable methods remain elusive
in a clinical setting today. Comprehensive panels of gene clusters are being developed
toward the generation of molecular signatures in order to better diagnose urologic
malignancies, and identify effective treatment strategies in the emerging era of
personalized medicine. In this review, we discuss the current literature on the credibility
and biomarker value of such molecular signatures in the context of clinical significance
relating to the pathological aggressiveness of urologic tumors (prostate, bladder and renal
cancer)—also exploiting their predictive potential in the response to treatment.
Keywords: miRNAs; vascularity; therapeutic resistance; circulating tumor cells;
prostate cancer; bladder cancer; renal cancer
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1. Introduction
In 2013, an estimated 58,610 deaths in the United States will result from prostate, bladder and
kidney cancers [1]. Despite a tremendous amount of research effort, reliable and non-invasive methods
for detecting malignancy and projecting disease course remain elusive in a clinical setting. Absence of
a singular marker of malignancy calls for a shift toward examining more comprehensive genetic
profiles of tumors, which has the enormous potential to provide treatment approaches tailored to
the individual. These molecular signatures, or unique genetic features distinguishing tumor cells
from normal tissue, have generated tremendous interest as a potential means to reliably identify
disease and progression.
The use of molecular signatures to detect and determine rate of progression in various cancers
represents the latest shift in moving toward identifying initial events contributing to early stage tumors,
ultimately allowing for optimizing therapeutic response and treatment outcomes. Indeed the need for
biomarkers with high predictive value in tumor progression to advanced disease and requiring less
invasive procedures (than characterization of tumor morphology) is now higher than ever for urologic
malignancies. Since the 1960’s, scoring of urologic tumors, such as the Gleason Score of prostatic
tumors based largely on morphological characteristics, has been common practice. “Primitive” as the
pursuit of morphological differences might seem, and with cell morphology alone proven to be an
imprecise predictor of cancer progression in the past, one must recognize that factors controlling tissue
architecture, cell polarity and signaling processes such as epithelial-mesenchymal-transition (EMT),
invasion and cell adherence may represent attractive options within a signature collection. EMT is now
viewed as an essential early step in cancer metastasis. Significantly the switching between cell
phenotypes that occurs during EMT is specified by certain microRNAs, (small non-coding RNAs
regulating gene expression post-transcriptionally), thus enabling expansion of the molecular platforms
for the pursuit of molecular signatures, towards predicting the metastatic course of cancer progression,
as well as therapeutic response. In this review, we discuss the increasingly recognized value of
biomarkers in molecular signatures and their impact on identification of the three major types of
urologic tumors—with a focus on projecting their clinical impact in patient diagnosis and treatment.
2. Prostate Cancer
Prostate cancer remains the second most common cancer-related death in men, and will result in
more than 29,720 estimated deaths in 2013 [1]. And with the characteristic slow progression for some
tumors and recurrence after treatment in many prostate cancer patients [2], the balance between
overaggressive and unneeded treatment coupled with the ability to identify cancers predisposed to
aggressive phenotypes remains a challenge. For decades, Prostate Specific Antigen (PSA) had served
as the de facto standard biomarker for prostate cancer detection. However, it is common knowledge
that even in the absence of elevated PSA values, prostate cancer can be present [3]—not uncommonly
resulting in false negatives. Wide variation in physiologically normal PSA values, as well as its
inconvenient modulation from several sources is a great source of concern for PSA’s clinical utility. In
2011, amid much controversy and intense discussions on a national and international platforms, the
U.S. Preventative Services Task Force concluded that “the potential benefit does not outweigh the
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harms,” with regard to the use of PSA screening as a means to prevent prostate cancer specific
mortalities in men [4]. In an era where the most utilized diagnostic marker for prostate cancer has
attracted such controversy among many and molecular landscapes and circulating tumor cells of
prostate cancer patients are effectively profiled, identification of detection methods with refined
sensitivity and precise specificity proceeds at a promising rhythm.
2.1. TMPRSS2:ETS Gene Fusions
Since their identification in 2005 by the pioneering studies of Arul Chinnayan [5], the
TMPRSS2:ETS gene fusions have been the focus of intense investigations, as well as a point of
contention with regards to its role in prostate cancer as an indicator for the aggressive phenotype. The
transmembrane serine protease TMPRSS2 is androgen regulated, and in response to ligand exposure,
fuses with members of the ETS family of transcriptional activators [6]. ERG is the most commonly
fused member of the ETS family, with a TMPRSS2:ETS fusion occurring in approximately 46% of
prostate cancers, in a study of needle biopsies in patients with prostatic malignancy [7]. An exact
consensus with regards to the prevalence of these gene fusions in prostate cancer has not been reached
due to different detection methods, varying sample sizes, as well as heterogeneity of fusions within the
tumor cells. Interestingly, much rigorous debate has surrounded the validity of this lone marker in
determining prostate cancer recurrence and mortality, and recent literature calls for a reevaluation of
using TMPRSS2:ETS fusions alone as prognostic indicators [8]. The important regulatory role of
androgens on the TMPRSS2:ETS fusion via interaction with the androgen receptor (AR) enables a new
promise for a potential role of the gene fusions in predicting the emergence of castration resistant
prostate cancer (CRPC). While primary prostate cancer has several treatment options ranging from
“active surveillance” to radical prostatectomy, all showing similar and extraordinarily high patient
survival rates—with 5 year survival approaching 100% [1], those men who develop CRPC have a poor
prognosis and are likely to die as a result of metastatic disease [9]. Androgen deprivation therapy
(ADT) is temporarily effective as a treatment strategy to impair prostate cancer by blocking circulating
testosterone levels, either by medical or surgical castration. Unfortunately, eventual progression to the
castration resistant phenotype is inevitable Sternberg [10].
Specifically relevant to the TMPRSS2:ETS fusions and the AR is the transitory dip in expression
immediately after androgen deprivation therapy [11]. However, TMPRSS2:ETS expression rises once
again to levels seen before ADT [11] as primary tumors develop into CRPC. One may argue in favor
of future applications to more accurately predict the appearance of the CRPC phenotype by comparing
a patient’s baseline and subsequent expression levels of TMPRSS2:ETS fusions. The potential benefit
to the patient and physician alike would be two-fold: firstly, serving as a more accurate indicator
of prognosis; secondly, allowing the physician to better time the introduction of second-line
chemotherapeutic agents.
2.2. The Androgen Receptor/Transcription Factor-Derived Molecular Signature
The primary target of ADT, the androgen receptor (AR) transcriptionally regulates a series of
growth response genes, the intricacies of which have challenged not only their therapeutic exploitation
towards the development of effective treatment strategies in CRPC, but also the identification of
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biomarkers better predicting tumor aggressiveness and ultimate lethality associated with advanced
disease. Recent elegant studies by Heemers and colleagues documented the role of the AR in
regulation of effector genes along with the transcription factor Serum Response Factor in a 158 gene
signature. The resultant androgen dependent gene signature indeed directly correlated with the
presence of aggressive disease, poor outcome, biochemical recurrence, as well as demonstrating the
ability to accurately distinguish malignant from benign prostate tissue [12]. Similarly striking results
were noted by Sharma et al. after exploring a 16 gene signature in CRPC, further highlighting the vital
role of persistent AR signaling in CRPC [13].
2.3. PTEN Loss
The loss of the Phosphatase and Tensin Homolog (PTEN) is another genetic aberration involved in
prostate cancer, as well as many other types of cancer. PTEN acts as a tumor suppressor by encoding
for a phosphatase protein product which is involved in cell cycle regulation [14]. Commonly found
with a TMPRSS2:ERG fusion, the concurrent loss of PTEN contributes to a poor prognosis in cancer in
the presence of an existing TMPRSS2:ERG fusion [15] with an increased risk of recurrence [16].
Although the functional dependence on gene fusions is not clear, PTEN has been shown to directly
influence tumor progression and early recurrence in both fusion positive and fusion negative
tumors [17]. Interestingly, PTEN loss has already shown its utility in an experimental panel of
molecular signatures. This four gene panel including PTEN, SMAD4, Cyclin D1, and SPP1
significantly outperformed Gleason scoring using data from the Physicians’ Health Survey cohort in
predicting lethal metastasis, and was further improved when combined with Gleason scoring [18].
2.4. Spink 1
Markers for detection and progression of prostate cancer do not completely hinge upon the presence
of a gene fusion product. Serine protease inhibitor Kazal type 1 (Spink 1), has been shown to be
present in a subtype of prostatic tumors not containing a TMPRSS2:ETS fusion [19]. The expression of
Spink1 in prostate tumors has shown promise as an independent predictor of biochemical recurrence
after resection; most excitingly, is able to be detected in the urine—making it a less-invasive
alternative to sampling previous biomarkers [20]. Unfortunately for future clinical application, Spink1
expression is elevated in the absence of a TMPRSS2:ETS fusion in only about 10% of cases [20].
2.5. Circulating Tumor Cells (CTCs)
In a novel attempt to further tailor treatment to the individual patient, methods of identifying and
capturing malignant cells that arise from primary or metastatic tumor sites have been developed. The
cell-capture techniques of “moving targets” are constantly improving and guided towards the detection
of CTCs in peripheral blood, becoming extremely valuable in the prognosis of cancer patients—in
both disease recurrence and likelihood of metastatic invasion [21]. High-cost, inefficient capturing and
relatively low levels of circulating CTCs in serum have challenged the routine clinical application and
prognostic value of CTCs. However, when CTCs are detected efficiently, initial studies have been
quite striking. Moreno et al. found a marked correlation between number of CTCs and mortality in
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patients with metastatic castration resistant prostate cancer; patients with >5 CTCs per 7.5 mL blood
had a median survival of 7 years compared with a median survival of 4 years for those patients having
<5 CTCs per 7.5 mL blood [22]. More recently, an exciting study from Memorial Sloan-Kettering
Cancer Center examined TMPRSS2:ERG gene fusion status in CTCs with outcomes in men with
CRPC. Men in this study treated with Abiraterone Acetate who demonstrated post therapeutic levels of
<5 CTCs per 7.5 mL blood benefitted from a median survival of 72 weeks longer than their cohorts
with post therapeutic levels of >5 CTCs per 7.5 mL [23].
2.6. The Clustering Value of MicroRNAs
MicroRNAs (miRNAs) represent a unique class of molecules recently discovered and classified as
small non-coding RNAs that regulate gene expression at the post-transcriptional level in eukaryotic
cells. Since their discovery, miRNAs have emerged as attractive and “sophisticated in their
cell-uncoded behavior” molecular species that may have therapeutic targeting value as well as
diagnostic potential in tumors. These short (usually ~22 nt) sequences are non-coding segments of
RNA regulating approximately 60% of human genes [24]; miRNAs have profound effects on vital
cellular functions—including key biological processes involved in tumorogenic transformation and
tumor progression to metastasis such as migration, proliferation, and apoptosis [25]. The cancer
phenotype can be equally promoted by miRNAs acting excessively on tumor suppressor genes as well
as the decreased regulation of proto-oncogenes by miRNAs. Cancer-specific miRNA fingerprints have
been identified in many types of cancers, including urologic tumors. Compelling evidence supports a
pivotal role for miRNAs in the regulation of cancer stem-like properties of prostate tumors [26] with
potential significance in the development of a special platform for molecular therapeutics impairing
early events in tumorigenesis, despite the complexity of these intriguing molecules (Figure 1).
Moreover certain miRNAs, for example miR32 and miR-145a, are upregulated by androgens in
prostate cancer.
Figure 1. Select miRNAs with potential diagnostic and prognostic utility in urologic
tumors, along with selected functions in tumorigenesis/progression of disease. Each
miRNA is differentially expressed in malignant states, and contributes to oncogenesis
(oncogene activation) or defective tumor suppressor function [27,28].
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2.7. miR-141
Although miRNAs might be considered still at their infancy, the emerging scenario of their
prominent role in determining future therapeutic strategies and translational outcomes is exciting and
rich with promise. Despite the relatively small size of miRNA species, many are robustly expressed in
sera of patients with prostate cancer; a study by Brase et al. noted that miR-141 served as a potent
diagnostic and prognostic indicator in a subset of prostate cancer patient’s sera [29]. Equally important
in miR-141’s value as a potential component of a molecular signature panel involves its specificity
for malignancies of the prostate, and even more precisely—the presence of aggressive prostate
cancer [30]. A schematic summary of several miRNAs found to have specific roles in urologic tumors
with potential utility in molecular signature panels is illustrated on Figure 1.
In 2010 and 2011, four new drugs achieved FDA approval targeting metastatic CRPC, bringing
much promise in implementation of clever drug design and optimization: Abiraterone Acetate, an
androgen biosynthesis inhibitor; cabazitaxel, an inhibitor of mitosis via actions on microtubules;
denosumab, targeting bone remodeling processes; sipuleucel-T, an immune system “boosting”
vaccine [31]. Moving forward, adaptations in the treatment of prostate cancer toward a systematic,
individualized treatment plan based on specific genetic events remains crucial. Further studies
elucidating greater understanding of molecular mechanisms functionally linking gene expression
profiles to critical processes orchestrating tumor cell behavior are required to further refine treatment
options and enhance therapeutic efficacy in patients with CRPC.
3. Bladder Cancer
Bladder cancer is the second most common malignancy of the genitourinary tract, and will account
for an estimated 15,210 deaths in the United States in 2013 [1]. Five-year relative survival rates remain
below 80% for patients diagnosed with bladder cancer [1], and decreasing with more aggressive stages
at detection. Bladder tumors and their characteristically high risk of recurrence present an immense
challenge in the clinical management of patients and therapeutic outcomes. Significantly enough, due
to high recurrence rates and surveillance requiring cystoscopy, bladder cancer is the most expensive
cancer to treat in the United States per case—with over half of its cost resulting from surveillance [32].
Growing evidence suggests the ability to predict those tumors with inherently greater risks of
recurrence, as well as tumors likely to remain superficial or to invade the bladder wall [33].
3.1. Methylation Elevates Genes to Biomarker Status
Exploitation of DNA methylation status in urine specimens of bladder cancer patients is a powerful
methodology toward the prediction of tumor presence and aggressiveness. In tumor cells, alterations in
DNA methylation of cytosine residues in the form of both hypermethylation and hypomethylation can
promote the cancer phenotype. Aberrant hypermethylation of CpG islands of DNA promoter regions
silences genes; common sites of hypermethylation in bladder cancer occur at the WT1, BRCA1, and
RARB genes [34]. Proteins encoded by these genes serve critical functions in regulating cell
differentiation and proliferation, loss of regulation due to methylation of promoter regions has serious
deleterious effects [34]—contributing to uncontrolled growth. Hypomethylation, on the other hand,
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frequently occurs in all regions except CpG islands of promoter regions, which induces genomic
instability and gene-specific hypomethylation also promoting carcinogenesis [31,32]. Currently, the
gold standard for noninvasive urinary diagnosis of bladder cancer is by urinary cytology—performed
by a pathologist or cytologist who categorizes cells in urine as normal, atypical/intermediate,
suspicious, or malignant. DNA methylation markers allow for total objectivity as opposed to urinary
cytology, and were shown to greatly improve sensitivity when compared with traditional diagnostic
strategies [35]. Urine samples are analyzed by two major techniques—methylation sensitive PCR
(MSP) and real-time PCR. MSP quantifies the number of methylated/nonmethylated cytosine residues
in comparison with reference standards [36]. Methylation markers are more frequently analyzed by
real-time PCR due to its low requirement for DNA compared to MSP [37].
4. Gene Mutations Shaping Marker Profiles: Really?
4.1. p53
Commonly referred to as the “guardian of the genome,” p53 is a significant regulator of the cell
cycle and functions as a tumor suppressor protein. The protein product of p53 tumor suppressor gene,
functions by directly binding DNA and repressing transcription of genes that promote growth and
invasion; in a malignant state, mutated p53 is unable to bind DNA, resulting in loss of p53’s vital
tumor suppressor function [38]. Mutations in the p53 gene are the most commonly occurring genetic
alterations in human cancers, including urologic tumors and often taking a leading causative role in
bladder cancer [39]. Clinicopathological evidence indicates that the presence of a mutant p53 in the
bladder urothelium results in a highly aggressive bladder tumor phenotype with a high risk of disease
specific mortality [40]. Certain polymorphisms, such as the Pro/Pro genotype at codon 72, have been
associated with bladder cancer progression—but fall short in predicting incidence [39]. The presence
of a p53 mutation, leading to abnormal p53 expression and impacting its function to prevent DNA
damage, may potentially serve as an initial physiological stress-factor concerning disease progression;
several limitations in its application however as a prognostic marker of bladder cancer must be
overcome [41].
4.2. FGF3R
Mutations in Fibroblast Growth Factor Receptor-3 (FGF3R) are more often found in low grade
urothelial carcinoma (LGUC) than in high grade urothelial carcinoma (HGUC). A study in 2011 found
FGFR3 mutations in 84% of LGUC, whereas a mutation was present in only 17% of HGUC samples,
which did reach statistical significance [42]. The presence of FGFR3 mutations has generally been
found to be associated with low tumor grade, early stage, and low recurrence rate—all leading to a
more favorable prognosis [40,43].
4.3. Survivin
As a member of the Inhibitor of Apoptosis (IAP) protein family, survivin plays a role in tumor
development and progression by inhibiting caspase activity [44]. Although examined in diverse human
malignancies, survivin in bladder cancer has been under significant study due to its near universal
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presence in bladder malignancy, present in 96.3% of samples in a study by Berrada et al. [45]. An
extensive systematic review by Ku et al. showed much greater sensitivity for detection of bladder
cancer than did traditional urine cytology [46]. Moreover, survivin has also shown merit as an
independent predictor of cancer-specific survival in an elegantly designed clinical study by Shariat and
colleagues, revealing that patients with altered survivin expression had a five-year cancer specific
survival of 72.9% versus 86.2% with normal survivin expression [47].
4.4. The p27 Halt on Cancer Cell Progression
The p27 gene encodes for a key cell cycle regulatory protein that interacts with cyclin-dependent
kinase E towards controlling entry into the cell cycle and ultimately cell proliferation. Over a decade
ago, the clinical correlation between loss of p27 protein expression and reduced survival of bladder
cancer patients was first documented by Del Pizzo, et al. [48]. Consequential to this seminal evidence,
additional studies reported that p27 expression inversely correlated with tumor stage and grade in
human bladder cancer [33,49]. While p27 was aggressively interrogated as a potential therapeutic for
several human malignancies, major culprits of p27 degradation have been elucidated. In normal tissue,
p27 functions to inhibit Cdk/cyclin complexes in the nucleus, largely regulating the cell’s journey from
G1 to S phase of mitosis. Impaired regulation of the phosphorylation cascade responsible for p27
degradation promotes cell cycle progression, and in turn, uncontrolled cell growth [50]. More recent
evidence indicated that mRNA transcribed from the SKP2 gene was highly elevated, and was once
again shown to degrade p27 [33]. Inhibiting the gene products of SKP2 carries much promise in terms
of therapeutic targeting value for the future management of bladder tumors harboring a mutation
impacting p27 degradation.
4.5. Integrin-Linked Kinase
Integrin-linked kinase (ILK) is a signaling and scaffolding protein that regulates cell survival,
proliferation, migration, and angiogenesis [51]. ILK gene expression is correlated with tumor
invasiveness of bladder cancer in humans, and plays an important role in metastasis [52], predisposing
tumors with high ILK expression to a more aggressive phenotype. In addition to showing promise as
an indicator of more aggressive, metastatic disease, ILK has displayed rather significant potential as a
therapeutic target in the treatment of bladder cancer. Knockdown of ILK gene expression by siRNAs
provides molecular targeting promise as a novel therapeutic strategy towards targeting the multiple and
occasionally functionally redundant downstream signaling effectors that play significant roles in
navigating cellular processes regulating EMT, inflammation, angiogenesis and anoikis. Diminishing
ILK expression and the resulting functional consequences on tumorigenesis are mechanistically
dictated by the following signaling pathways, inhibition of AKT survival pathway, leading to
increased apoptosis of tumor cells; reduction of expression of matrix metalloproteinase-2 (MMP-2)
and MMP-9, and upregulation of nm23-H1, a potent suppressor gene of metastasis, impairing
angiogenesis, vascularity and metastasis [53].
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4.6. miR-145 and miR-200a
Yun et al. recently reported two novel miRNAs (miR-145 and miR-200a) present and stable in
urine of bladder cancer patients. In addition to being cell-free and detectable in urine, each of the
miRNAs individually demonstrated potential utility in detection and prognostic value in bladder
malignancies; miR-145 demonstrated significant correlation with grade, where miR-200a served as an
independent predictor of recurrence [54]. Further studies involving exploitation of key mechanistic
pathways navigated by these miRNAs will enable validation of their prognostic value in larger
numbers of patient cohorts.
5. Kidney Cancer
Renal cell carcinoma (RCC) presents a unique challenge for clinicians and investigators alike due to
the vast heterogeneity in renal malignancies. As recently as 2012, there were only six FDA approved
agents for treatment of RCC, mainly targeting angiogenesis and the mammalian target of rapamycin
(mTOR) signaling pathways [55] for the five types of RCC. In 2005, virtually no therapy past surgical
intervention and cytokine treatments were available. Even then, cytokine treatment provided only a
small chance of long-term benefit, with only approximately 15% of patients showing response to
interferon-alpha or IL-2 [56]. Total five-year survival rates in patients with renal malignancies in the
years 2001–2007, although significantly improved, remain at only 71% [1]. With 65,150 expected
diagnoses of RCC in 2013 and over 13,680 expected deaths as a result [1], marked improvement in the
number of treatment options coupled with enhanced efficacy of those options is essential. While there
have been significant advances in the development treatment strategies over the last decade targeting
malignancies of the kidney, the search for biomarkers with solid prognostic value, specific to renal cell
carcinoma has met with considerably less creativity. Central to the understanding of the pathogenesis
of RCC is the recognition that an overwhelming majority of molecular markers discovered thus far for
RCC are heavily involved in the regulation of angiogenesis, underscoring the role of angiogenesis as
critical contributor to the development and progression of RCC, characterized for its extensive
vascularization. Neovascularization of tumors is an important process intimately linked to cancer
progression and metastasis—as advanced tumor growth is dependent upon excessive angiogenesis
in order to access oxygen and nutrients for metabolism. The reactive stroma in the dynamic
microenvironment of a developing tumor may also play a primary role in recruiting endothelial cells
towards expansive tumor neovascularization and metastatic spread.
5.1. Von Hippel Lindau (VHL) Mutation/Hypoxia Inducing Factor 1-alpha (HIF-1α)
The hypoxia response signaling emerges as a therapeutic target for renal cancer via its causal
imposition on tumor vascularity. In response to oxygen changes in the tumor microenvironment,
hypoxia inducing factor-α induces angiogenesis [51]. Von Hippel Lindau mutations, found in
34%–57% of Clear Cell Renal Cell Carcinoma (ccRCC), cause the dramatically reduction in
breakdown of HIF-1α and promote its nuclear translocation, that subsequently transcriptionally
activates the master pro-angiogenic gene, VEGF [57]. In addition to its angiogenic effects, HIF-1α
possesses a multitude of downstream targets, functionally contributing to cell migration and pH
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modification [58]. Consequently, stabilization of increased HIF-1α levels due to VHL gene defects
leads to greater probability of metastatic recurrence coupled with lower overall survival rates when
compared to renal malignancies not possessing a VHL mutation, and has long been established [59].
HIF-1α is involved in upregulating cytokine receptors, specifically CXCR4, that promotes metastasis
to specific tissues [60]. The impact of pH modification is discussed below in the context of Carbonic
Anhydrase IX function which presents promising value as component of a molecular signature panel
in RCC.
5.2. Carbonic Anhydrase IX (CAIX)
Fitting the mold as a marker showing relative specificity for clear cell renal carcinoma (ccRCC),
CAIX has been identified as an enzyme not present in normal renal tissue, but is present in as
many as 97% of ccRCC tumors [61]. Carbonic Anhydrase IX is strongly up-regulated in tumors
under hypoxic conditions, and is partially responsible for the acidification of the extracellular
environment [56]. Acidification of the extracellular matrix promotes tumorigenic transformation,
chromosomal rearrangements, extracellular matrix breakdown, and induction of cell growth factor
expression [62,63]. CAIX protein expression is strongly correlated with outcome in patients with
ccRCC, but its use as an independent marker of prognosis remains suspect [61]. To date, CAIX is
undoubtedly one of the most well-defined markers specific to ccRCC; however, its limited validity
when used independently calls for the clever application of a molecular signature involving a panel of
biomarkers for the purpose of stratifying patients into distinct groups based upon risk of disease
progression and mortality.
5.3. β-Catenin
The Wnt signaling pathway is a critical regulator of embryonic development, and serves a major
role in maintaining cell homeostasis throughout adulthood [64]. Disruption of the Wnt pathway
ultimately leads to increased levels of a critical transcriptional coactivator β-catenin; accumulation of
β-catenin leads to transcriptional activation of genes regulating processes involved in malignant
development, including proliferation, survival, and differentiation [24]. Accumulation of β-catenin
levels is a result of faulty degradation in the cytoplasm by the ubiquitin-protease complex [24].
Significantly enough, mechanistic elucidation of the Wnt signaling pathway identified the functional
involvement of the VHL suppressor gene with β-catenin signaling action in tumor cells [65]. Under
normal
physiological
conditions,
VHL
suppressor
protein
possesses
an
E3-ubiquitin ligase that functions to degrade β-catenin, this loss of function in the VHL protein
conferred by mutation of the VHL gene affects β-catenin levels in the cell—linking the Wnt signaling
pathway to renal malignancy [65].
5.4. Hypoxia Induced Factor-2 Alpha (HIF-2α)
HIF-2α is a protein at least partially responsible for regulating the transcription of genes related to
erythropoiesis and angiogenesis, glycolysis, and vasodilation [66]. HIF-2α has been implicated in
several cancers in addition to RCC, although by engaging a differential hypoxia-mediated pathway

Int. J. Mol. Sci. 2013, 14

18431

than CAIX [67]. Both CAIX and HIF-2α are independent predictors of outcomes in patients with
certain malignancies, and their value in combination was shown to be additive [67]. Further studies on
the role of hypoxia and its close association with renal cancer hold potentially high clinical
significance in the treatment of patients with RCC.
5.5. miR-34a
The existing evidence is rather contradicting, as miR-34a has been shown to be elevated in kidney
cancer, while it is markedly downregulated in other human malignancies, opening the possibility of
miR-34a overexpression as a specific diagnostic marker for renal cell carcinoma [68]. In the
same study, it was also established that functional loss of miR-34a markedly inhibited cell
proliferation in renal cell carcinoma, providing strong support for the contribution of this molecule to
the development of RCC.
6. Optimizing Discovery Platforms
Advancements in technology such as high throughput DNA microarrays have revolutionized the
efficiency with which researchers are able to catalogue variance in genetic expression between healthy
cells and particular types of tumors. However, just as important as gathering vital information is the
ability to fully interpret it—which is currently the major obstacle in applying these gene expression
profiles for therapeutic use. Downstream effects not yet studied or regulatory steps not yet elucidated
or fully understood remain problematic in developing effective treatments tailored to a tumor’s
molecular signature. Herein lies another obstacle for clinically significant biomarkers of malignancy in
the context of yet-to-be-elucidated molecular pathways—ensuring that “new” markers affecting
survival are not purely a product of lead-time bias, but are relevant to carcinogenesis and represent
tangible therapeutic targets.
7. Conclusions
Global translational research efforts continue, with a focus on the optimization of highly-efficacious
therapeutic strategies that benefit patients through the development of treatments fitted to unique
genetic and pathophysiological characteristics. Considering the cellular multiplicity (in the context of
the microenvironment) and the diversity of the genetic factors contributing to cancer incidence such as
the patient genetics and family history, exposure to various diets, lifestyles and cellular heterogeneity
that characterizes a multistep, multifactorial disease call for novel treatments tailored to the molecular
dynamics of individual tumors—ultimately toward optimization of outcomes in a personalized
medicine approach. Identifying the cellular and molecular landscape of individual tumors (EMT,
inflammation, growth kinetics, gene methylation status) and targeting the initial molecular events
triggering manifestation of tumorigenic growth would allow effective targeted therapeutic strategies
and successful clinical outcomes. Collection of gene signatures, including miRNAs panels, hold great
promise in enabling investigators to proceed with an accurate diagnosis and physicians to provide
patients with appropriately optimized treatment strategies selectively impairing their tumors,
eventually leading to cancer prevention and improved quality of life.
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